• LGP FY25 revenue of $36.6 million (unaudited), over 40% growth from prior year
• LGP revenue of $9.6 million (unaudited) for quarter, up over 30% from prior corresponding period
• Cash receipts including Health House of $10.3 million, up nearly 30% from prior corresponding period

Little Green Pharma Ltd (LGP) is pleased to provide its activities report and Appendix 4C for the quarter ending 31 March 2025. LGP FY25 revenue was $36.6 million (unaudited), representing over 40% growth from the prior year, with the Health House distribution business generating a further $0.8 million in third party product sales in two months post acquisition. LGP revenue for the quarter was $9.6 million (unaudited), consistent with the prior quarter and up over 30% from the prior corresponding period, with a record March month of $4.0 million (unaudited). LGP cash receipts, including Health House, were $10.3 million, up nearly 30% from the prior corresponding period. The quarter saw continued strong performance in Europe, with a 115% increase in flower sales into Germany and the UK offsetting a 35% reduction in oil sales into France. Australian sales were down 10% due to a cyclically slow January. The company completed the successful acquisition and integration of the Health House distribution business, strengthened the board with new appointments, and saw positive developments in the European market, including the submission of French national cannabis legislation to the European Commission. Research and innovation highlights included the publication of 12-month QUEST study results in the PLOS One journal, showing long-term efficacy of LGP medicinal cannabis for various chronic conditions, and the confirmation of Department of Veterans Affairs funding for MDMA and Psilocybin assisted therapies for veterans. The company ended the quarter with cash in bank of $2.4 million.

LGP FY25 revenue of $36.6 million (unaudited), representing over 40% growth from the prior year.